Detalles de la búsqueda
1.
Increasing Annual Cancer Incidence in Patients Age 20-49 Years: A Real-Data Study.
JCO Glob Oncol
; 10: e2300363, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38513186
2.
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Front Immunol
; 15: 1293931, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38469299
3.
Ability of final PET/CT to predict response to first-line treatment in real patients with classical Hodgkin lymphoma.
Int J Hematol
; 115(1): 54-60, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34546542
4.
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Clin Cancer Res
; 28(17): 3658-3668, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35727601
5.
Liquid Biopsy as a Tool for the Characterisation and Early Detection of the Field Cancerization Effect in Patients with Oral Cavity Carcinoma.
Biomedicines
; 9(10)2021 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34680596
6.
Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model.
Ther Adv Med Oncol
; 13: 1758835920984061, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33747147
7.
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
J Immunother Cancer
; 9(6)2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34158317
8.
Targeted treatment approaches in refractory germ cell tumors.
Crit Rev Oncol Hematol
; 143: 130-138, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31634730
Resultados
1 -
8
de 8
1
Próxima >
>>